SOHO 2023 Eleventh Annual Meeting

 

SOHO 2023 Eleventh Annual Meeting
Avatar

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

By SOHO 2023 Eleventh Annual Meeting FEATURING Eytan Stein
By SOHO 2023 Eleventh Annual Meeting FEATURING Eytan Stein
25 views
September 29, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Leukemia
37:10
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CML and Pregnancy

Feat. E. Abruzzese
11:02
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: AML

Feat. F. Ravandi
57:31
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: ‘Level Up’ With Personalized Care for CLL/SLL - Achieving…

Feat. W. Wierda, N. Lamanna, M. Thompson
10:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: CLL

Feat. N. Jain
10:37
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: CML

Feat. P. Rousselot
10:16
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: ALL

Feat. E. Jabbour
13:18
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is New in the WHO Classification of AML?

Feat. S. Loghavi
15:12
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is New in the ICC Classification of AML?

Feat. R. Hasserjian
10:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: How Do We Reconcile These AML Classifications in Clinical…

Feat. A. Wei
16:55
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Post-Transplant Maintenance Therapy for Patients With AML:…

Feat. B. Oran
15:27
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Prior Therapy Not Needed for Transplanting Patient…

Feat. J. Schetelig
12:17
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Achieving Best Response Is Desirable Prior to Allo…

Feat. R. Walter
16:11
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Familial Predisposition to AML: Prevalence & Implicati…

Feat. L. Godley
08:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Impact of Consolidation Chemo Intensity Before Allogeneic…

Feat. Y. Hicheri
15:01
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Patients With AML and Active Disease Should Be Tra…

Feat. H. Fernandez
13:59
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Against Allogeneic Transplantation for AML Patient…

Feat. E. Waller
12:48
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Genomic Complexity Beyond BCR::ABL1 and Its Clinical Impa…

Feat. D. Ross
13:31
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Epigenetic Dysregulation of CML

Feat. T. Ong
16:25
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

Feat. N. Cross
07:50
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Phase II PACE Trial 5-Year Data: Early Cytogenetic or Mole…

Feat. H. Kantarjian
15:49
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: How Biologic Markers Impact CLL Outcomes With Novel Thera…

Feat. T. Munir
16:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Clinical Significance of MBL

Feat. S. Parikh
15:57
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is the Future of Menin Inhibitors in AML?

Feat. G. Issa
15:40
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CNS Prophylaxis in ALL

Feat. P. Kebriaei
09:01
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Sequencing Immunotherapies in Adults With B-ALL

Feat. B. Shah
15:23
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T

Feat. J. Park
07:04
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Comparison of Treatment Outcomes in Adolescents and Young…

Feat. O. Shahin
08:21
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Results from the QuANTUM-First Trial: Impact of allo-HCT i…

Feat. A. Perl
13:39
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Triplet Regimens in AML: Beyond Azacitidine + Venetoclax

Feat. C. DiNardo
23:11
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Navigating the Treatment Value of TKIs in CML in the Era …

Feat. H. Kantarjian
08:35
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Primary Analysis of the Phase 1/2, Single-Arm, Multicenter…

Feat. T. Siddiqi
17:30
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Rational TKI Choice in CML

Feat. M. Deininger
17:27
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: How We Developed a Curative Therapy for CLL and Stopped U…

Feat. J. Seymour
16:04
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Is Finite Duration Therapy the New Standard of Treatment …

Feat. A. Ferrajoli
26:59
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Debate: MRD+ After 1 Year of VenG in CLL - Stop or Continu…

Feat. O. Al-Sawaf, N. Lamanna
19:15
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CML - Are We Doing It Right?

Feat. J. Cortés
20:29
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Slow-Motion Therapeutic Revolution in Adult ALL

Feat. H. Kantarjian
15:34
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Is AML With Monocytic Features a Separate Entity?

Feat. D. Pollyea
18:13
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is the Role of Quizartinib in the Current Landscape …

Feat. H. Erba
08:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 First Report of Phase 3 PhALLCON Study: Comparing Ponatini…

Feat. E. Jabbour
17:45
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Acute Leukemia of Ambiguous Lineage

Feat. C. Saygin
15:25
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Management of Newly Diagnosed Ph+ ALL: Novel Drugs and Str…

Feat. E. Jabbour
13:15
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

Feat. E. Stein
15:42
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Approach to Ph-Like ALL

Feat. I. Iacobucci